Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Guselkumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA OKs TREMFYA: Only IL-23 Proven to Stop Joint Damage
    FDA OKs TREMFYA: Only IL-23 Proven to Stop Joint Damage

    28 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-approves-label-expansion-cementing-tremfya-as-the-only-il23-inhibitor-proven-to-help-stop-further-joint-damage-302785103.html

    PR NEWSWIRE
    28 May 2026
    Share Share
    J&J: TREMFYA First IL-23 to Show Efficacy in Perianal CD
    J&J: TREMFYA First IL-23 to Show Efficacy in Perianal CD

    05 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/johnson--johnson-study-shows-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-efficacy-in-perianal-fistulizing-crohns-disease-302760610.html

    PR NEWSWIRE
    05 May 2026
    Share Share
    J&J's JNJ-4804 Shows Potential in Refractory bowel disease (IBD)
    J&J's JNJ-4804 Shows Potential in Refractory bowel disease (IBD)

    05 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/johnson--johnson-investigational-co-antibody-therapy-jnj-4804-shows-potential-to-raise-the-bar-for-clinical-efficacy-in-treating-refractory-inflammatory-bowel-disease-302761831.html

    PR NEWSWIRE
    05 May 2026
    Share Share
    Guselkumab Maintains Ulcerative Colitis Remission For 3 Years
    Guselkumab Maintains Ulcerative Colitis Remission For 3 Years

    21 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tremfya-guselkumab-long-term-data-show-sustained-clinical-and-endoscopic-remission-in-ulcerative-colitis-through-3-years-302693880.html

    PR NEWSWIRE
    21 Feb 2026
    Share Share
    J&J's Tremfya Roars Into 2026 With Massive January TV Ad Spend
    J&J's Tremfya Roars Into 2026 With Massive January TV Ad Spend

    11 Feb 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/jjs-tremfya-roars-2026-massive-tv-ad-spend-trailed-abbvies-rinvoq-and-skyrizi

    FIERCE PHARMA
    11 Feb 2026
    Share Share
    Europe Greenlights TREMFYA For Pediatric Plaque Psoriasis
    Europe Greenlights TREMFYA For Pediatric Plaque Psoriasis

    19 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-19/european-commission-approves-tremfya-guselkumab-for-the-treatment-of-children-with-plaque-psoriasis-marking-the-first-paediatric-indication-for-an

    PHARMIWEB
    19 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.